



# Managed Financial Conflicts of Interest (FCOIs) with Research Funded by the Public Health Service (PHS)

Current as of September 8, 2021

1.

**Date Disclosed:** April 22, 2013

**Investigator with FCOI:** William Federspiel, Ph.D.

**Title:** Professor of Chemical Engineering, Surgery and Bioengineering

**PHS Funding:** NIH 1 R0 1HL117637-01 *Paracorporeal Ambulatory Assist Lung*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** ALung Technologies, Inc.

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh; consulting; reimbursed/sponsored travel; equity interest

**Approximate dollar value of the SFI:** Consulting income and reimbursed/sponsored travel between \$20,000 – \$39,000; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

2.

**Date Disclosed:** August 19, 2013

**Investigator with FCOI:** Bruce Freeman, Ph.D.

**Title:** Professor and Chair of Pharmacology and Chemical Biology

**PHS Funding:** NIH 4 R37 HL058115-17 *Redox Transduction of Nitric Oxide Signaling*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

3.

**Date Disclosed:** August 19, 2013

**Investigator with FCOI:** Francisco Schopfer, Ph.D.

**Title:** Research Associate Professor of Pharmacology and Chemical Biology

**PHS Funding:** NIH 4 R37 HL058115-17 *Redox Transduction of Nitric Oxide Signaling*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.

**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Complexa, Inc.

**Approximate dollar value of the SFI:** Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

4. *FCOI eliminated August 31, 2018*

**Date Disclosed:** July 31, 2014

**Investigator with FCOI:** Stephen H. Thorne, Ph.D.

**Title:** Assistant Professor of Cell Biology

**PHS Funding:** NIH 1 R01 CA178766-01A1 *Creation of Immuno-Oncolytic Viruses for Cancer Therapy*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Western Oncolytics

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Western Oncolytics; equity interest

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

5.

**Date Disclosed:** February 17, 2015

**Investigator with FCOI:** Lee M. Ritterband, Ph.D.

**Title:** Professor of Psychiatry and Neurobehavioral Sciences, University of Virginia

**PHS Funding:** NIH 4 UH 3HL125103-01 *Pragmatic Trial of Behavioral Interventions for Insomnia in Hypertensive Patients*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** BeHealth Solutions, LLC

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Virginia and licensed to BeHealth Solutions, LLC; equity interest

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

6.

**Date Disclosed:** March 20, 2015

**Investigator with FCOI:** Mark H. Yazer, M.D.

**Title:** Professor of Pathology  
**PHS Funding:** NIH HHSN 268201100004 *Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Octapharma  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** \$5,000 – \$9,999

7.

**Date Disclosed:** April 30, 2015  
**Investigator with FCOI:** Louis D. Faló, Jr., M.D., Ph.D.  
**Title:** Professor and Chair of Dermatology  
**PHS Funding:** 5 P50 CA121973-07 (Sub-project ID: 7388) *SPORE in Skin Cancer*  
**Role on Research Project:** Principal Investigator of bench and animal, and Co-Investigator of human subject, research  
**Name of Entity in which Significant Financial Interest (SFI) is held:** SkinJect  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SkinJect; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

8.

**Date Disclosed:** May 14, 2015  
**Investigator with FCOI:** Saul Shiffman, Ph.D.  
**Title:** Professor of Psychology  
**PHS Funding:** NIH 5 R01 DA034629-02 *Cessation in Non-Daily Smokers: a RCT of NRT with Ecological Momentary Assessment*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Reynolds American, Inc.; Nicovum (a subsidiary of Reynolds American, Inc.); JSR, LLC  
**Nature of the SFI:** Consulting with Reynolds American and Nicovum; reimbursed/sponsored travel from Reynolds American; intellectual property rights (e.g., royalties, patents, copyrights) assigned to JSR; equity interest in JSR  
**Approximate dollar value of the SFI:** Consulting income between \$500,000 - \$549,999; reimbursed/sponsored travel between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

9. *FCOI eliminated June 7, 2019*

**Date Disclosed:** May 28, 2015  
**Investigator with FCOI:** Dario Vitturi, Ph.D.  
**Title:** Research Instructor, Department of Pharmacology & Chemical Biology  
**PHS Funding:** NIH R37 HL058115 *Redox transduction of nitric oxide signaling*

**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** \$10,000 - \$19,999

10. *FCOI eliminated June 13, 2019*

**Date Disclosed:** August 11, 2015  
**Investigator with FCOI:** Stacy Gelhaus Wendell, Ph.D.  
**Title:** Research Assistant Professor of Pharmacology & Chemical Biology  
**PHS Funding:** NIH R37 HL058115 *Redox transduction of nitric oxide signaling*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** \$10,000 - \$19,999

11.

**Date Disclosed:** August 13, 2015  
**Investigator with FCOI:** Francisco Schopfer, Ph.D.  
**Title:** Research Associate Professor of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 1 R01 AR066548-01A1 *The Immunoregulatory Effects of Electrophilic Fatty acids on Psoriasis*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Complexa, Inc.  
**Approximate dollar value of the SFI:** Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

12. *FCOI eliminated April 12, 2019*

**Date Disclosed:** August 18, 2015  
**Investigator with FCOI:** Mark Gladwin, M.D.  
**Title:** Professor and Chair of Medicine  
**PHS Funding:** NIH 1 K23 HL124051-01A1 *Nitrite Modulation of Hypertension, Platelet Activation and Mitochondrial Function*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** National Institutes of Health  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the National Institutes of Health and licensed to Mast Therapeutics  
**Approximate dollar value of the SFI:** \$1 - \$4,999

13. *FCOI eliminated August 25, 2016*

**Date Disclosed:** February 3, 2016

**Investigator with FCOI:** Fuchiang (Rich) Tsui, Ph.D.

**Title:** Research Assistant Professor of Biomedical Informatics

**PHS Funding:** NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Vervtality

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

14. *FCOI eliminated April 26, 2017*

**Date Disclosed:** February 8, 2016

**Investigator with FCOI:** James Eles

**Title:** Graduate Student, Department of Bioengineering

**PHS Funding:** NIH R01 NS062019 *Biomimetic Surfaces for Neural Implants*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

15. *FCOI eliminated April 26, 2017*

**Date Disclosed:** February 8, 2016

**Investigator with FCOI:** Xinyan (Tracy) Cui

**Title:** Professor of Bioengineering

**PHS Funding:** NIH R01 NS062019 *Biomimetic Surfaces for Neural Implants*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

16. *FCOI eliminated July 14, 2017*

**Date Disclosed:** February 12, 2016

**Investigator with FCOI:** Edward Prochownik, M.D., Ph.D.

**Title:** Professor of Pediatrics and Microbiology & Molecular Genetics

**PHS Funding:** NIH 1 U54 CA199092-01 *Center for Multiple Myeloma Nanotherapy*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

17.

**Date Disclosed:** February 22, 2016

**Investigator with FCOI:** Andrew Hinck, Ph.D.

**Title:** Visiting Professor of Structural Biology

**PHS Funding:** NIH R01 CA172886 *Inhibition of the Tumor-Promoting Effects of TGF-Beta in Advanced Prostate Cancer*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Texas Health Science Center at San Antonio

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Texas Health Science Center at San Antonio

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

18. *FCOI eliminated August 8, 2018*

**Date Disclosed:** April 25, 2016

**Investigator with FCOI:** Rebecca Jacobson, M.D., M.S.

**Title:** Professor of Biomedical Informatics and Pathology

**PHS Funding:** NIH U24 CA180921 *Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** NEXI

**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

19. *FCOI eliminated August 8, 2018*

**Date Disclosed:** April 25, 2016

**Investigator with FCOI:** Girish Chavan

**Title:** Staff, Department of Biomedical Informatics

**PHS Funding:** NIH U24 CA180921 *Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** NEXI

**Nature of the SFI:** Equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**20.** *FCOI eliminated August 8, 2018*

**Date Disclosed:** April 25, 2016

**Investigator with FCOI:** Eugene Tseytlin

**Title:** Staff, Department of Biomedical Informatics

**PHS Funding:** NIH U24 CA180921 *Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** NEXI

**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**21.** *FCOI eliminated June 7, 2019*

**Date Disclosed:** May 16, 2016

**Investigator with FCOI:** Dario Vitturi, Ph.D.

**Title:** Research Instructor, Department of Pharmacology & Chemical Biology

**PHS Funding:** NIH U01 HL117721 *Cellular and Molecular Mechanisms of Acute Lung Injury in Sickle Cell Disease*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$10,000 - \$19,999

**22.**

**Date Disclosed:** June 9, 2016

**Investigator with FCOI:** Joseph Glorioso, Ph.D.

**Title:** Professor, Department of Microbiology & Molecular Genetics

**PHS Funding:** NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

**Role on Research Project:** Principal Investigator of bench research and Co-Investigator of animal research

**Name of Entity in which Significant Financial Interest (SFI) is held:** Oncorus

**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

**Approximate dollar value of the SFI:** Consulting income between \$100,000 - \$149,999; equity interest between \$450,000 - \$499,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**23.**

**Date Disclosed:** June 9, 2016

**Investigator with FCOI:** Paola Grandi, Ph.D.

**Title:** Assistant Professor, Department of Neurological Surgery

**PHS Funding:** NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Oncorus

**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

**Approximate dollar value of the SFI:** Consulting income between \$100,000 - \$149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**24.**

**Date Disclosed:** June 9, 2016

**Investigator with FCOI:** Justus Cohen, Ph.D.

**Title:** Research Instructor, Department of Microbiology & Molecular Genetics

**PHS Funding:** NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**25.**

**Date Disclosed:** June 9, 2016

**Investigator with FCOI:** William Goins, Ph.D.

**Title:** Research Assistant Professor, Department of Microbiology & Molecular Genetics

**PHS Funding:** NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

**Role on Research Project:** Principal Investigator and Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Oncorus

**Nature of the SFI:** Consulting; equity interest

**Approximate dollar value of the SFI:** Consulting income between \$5,000 - \$9,999; equity interest between \$5,000 - \$9,999.



26.

**Date Disclosed:** June 9, 2016

**Investigator with FCOI:** Nduka Amankolor, M.D.

**Title:** Assistant Professor, Department of Neurological Surgery

**PHS Funding:** NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Oncorus

**Nature of the SFI:** Consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

**Approximate dollar value of the SFI:** Consulting income between \$5,000 - \$9,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

27. *FCOI eliminated November 30, 2018*

**Date Disclosed:** June 13, 2016

**Investigator with FCOI:** Paola Grandi, Ph.D.

**Title:** Assistant Professor, Department of Neurological Surgery

**PHS Funding:** NIH R01 CA175052 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Oncorus

**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

**Approximate dollar value of the SFI:** Consulting income between \$100,000 - \$149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

28.

**Date Disclosed:** June 13, 2016

**Investigator with FCOI:** William Goins, Ph.D.

**Title:** Research Assistant Professor, Department of Microbiology & Molecular Genetics

**PHS Funding:** NIH R01 CA175052 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Oncorus

**Nature of the SFI:** Consulting; equity interest

**Approximate dollar value of the SFI:** Consulting income between \$5,000 - \$9,999; equity interest between \$5,000 - \$9,999.

29.

**Date Disclosed:** June 13, 2016

**Investigator with FCOI:** Nduka Amankolor, M.D.

**Title:** Assistant Professor, Department of Neurological Surgery  
**PHS Funding:** NIH R01 CA175052 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Oncorus  
**Nature of the SFI:** Consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus  
**Approximate dollar value of the SFI:** Consulting income between \$5,000 - \$9,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**30.** *FCOI eliminated October 3, 2016*

**Date Disclosed:** June 28, 2016  
**Investigator with FCOI:** Michael McClincy, M.D.  
**Title:** Fellow, Massachusetts General Hospital  
**PHS Funding:** NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**31.**

**Date Disclosed:** June 28, 2016  
**Investigator with FCOI:** Kevin Bell, Ph.D.  
**Title:** Research Assistant Professor, Department of Orthopaedic Surgery  
**PHS Funding:** NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**32.** *FCOI eliminated August 25, 2016*

**Date Disclosed:** June 28, 2016  
**Investigator with FCOI:** Robert Hartman, Ph.D.  
**Title:** Postdoctoral Associate, Department of Physical Medicine & Rehabilitation  
**PHS Funding:** NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**33.** *FCOI eliminated September 2, 2016*

**Date Disclosed:** June 28, 2016

**Investigator with FCOI:** Xinyan (Tracy) Cui

**Title:** Professor of Bioengineering

**PHS Funding:** NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**34.** *FCOI eliminated September 2, 2016*

**Date Disclosed:** June 28, 2016

**Investigator with FCOI:** James Eles

**Title:** Graduate Student, Department of Bioengineering

**PHS Funding:** NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**35.** *FCOI eliminated July 19, 2017*

**Date Disclosed:** July 1, 2016

**Investigator with FCOI:** Joel S. Greenberger, M.D.

**Title:** Professor and Chair of Radiation Oncology

**PHS Funding:** NIH 2 U19 AI068021-11 *Signature-Directed, Sequential Delivery of Radiation Mitigators*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

36. *FCOI eliminated July 19, 2017*

**Date Disclosed:** July 1, 2016

**Investigator with FCOI:** Michael W. Epperly, Ph.D.

**Title:** Associate Professor of Radiation Oncology

**PHS Funding:** NIH 2 U19 AI068021-11 *Signature-Directed, Sequential Delivery of Radiation Mitigators*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

37. *FCOI eliminated August 4, 2017*

**Date Disclosed:** July 5, 2016

**Investigator with FCOI:** Shivalingappa Swamynathan, Ph.D.

**Title:** Associate Professor of Ophthalmology and Cell Biology

**PHS Funding:** NIH 5 R01 EY022898-03 *Corneal Expression and Function of Slurp1*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

38. *FCOI eliminated August 4, 2017*

**Date Disclosed:** July 5, 2016

**Investigator with FCOI:** Sudha Swamynathan

**Title:** Research Technician, Department of Ophthalmology

**PHS Funding:** NIH 5 R01 EY022898-03 *Corneal Expression and Function of Slurp1*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

39. *FCOI eliminated July 6, 2020*

**Date Disclosed:** July 13, 2016

**Investigator with FCOI:** Yuri Nikiforov, M.D., Ph.D.

**Title:** Professor of Pathology

**PHS Funding:** NIH 2 P50 CA097190-11 *Head and Neck Cancer SPORE*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to UPMC

**Approximate dollar value of the SFI:** \$100,000-\$149,999

40.

**Date Disclosed:** July 14, 2016

**Investigator with FCOI:** Bruce Freeman, Ph.D.

**Title:** Professor and Chair of Pharmacology and Chemical Biology

**PHS Funding:** NIH 1 R21 AI122071-01A1 *The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

41. *FCOI eliminated June 13, 2019*

**Date Disclosed:** July 14, 2016

**Investigator with FCOI:** Stacy Gelhaus Wendell, Ph.D.

**Title:** Research Assistant Professor of Pharmacology & Chemical Biology

**PHS Funding:** NIH 1 R21 AI122071-01A1 *The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology*

**Role on Research Project:** Principal Investigator of bench, and Co-Investigator on human subject, research

**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$10,000 - \$19,999

42. *FCOI eliminated May 4, 2020*

**Date Disclosed:** August 9, 2016

**Investigator with FCOI:** Dario A. Vignali, Ph.D.

**Title:** Professor and Vice Chair of Immunology

**PHS Funding:** NIH 9 R01 CA203689-07A1 *Interleukin-35 and the Tumor Microenvironment*

**Role on Research Project:** Principal Investigator of bench, and Co-Investigator on non-bench, research

**Name of Entity in which Significant Financial Interest (SFI) is held:** Tizona Therapeutics

**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the St. Jude Children's Research Hospital and licensed to Tizona Therapeutics;

**Approximate dollar value of the SFI:** Consulting income between \$60,000 - \$79,999; licensing proceeds from intellectual property rights between \$10,000 - \$19,999; equity interest is SFI whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**43.**     *FCOI eliminated July 14, 2021*

**Date Disclosed:** August 23, 2016

**Investigator with FCOI:** Bruce Freeman, Ph.D.

**Title:** Professor and Chair of Pharmacology and Chemical Biology

**PHS Funding:** NIH 1 K01 HL133331-01 *Protection against sickle cell disease nephropathy by nitrated fatty acids*

**Role on Research Project:** Primary Mentor

**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**44.**     *FCOI eliminated June 7, 2019*

**Date Disclosed:** August 23, 2016

**Investigator with FCOI:** Dario Vitturi, Ph.D.

**Title:** Research Instructor, Department of Pharmacology & Chemical Biology

**PHS Funding:** NIH 1 K01 HL133331-01 *Protection against sickle cell disease nephropathy by nitrated fatty acids*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$10,000 - \$19,999

**45.**     *FCOI eliminated July 14, 2021*

**Date Disclosed:** August 23, 2016

**Investigator with FCOI:** Francisco Schopfer, Ph.D.

**Title:** Research Associate Professor of Pharmacology and Chemical Biology

**PHS Funding:** NIH 1 K01 HL133331-01 *Protection against sickle cell disease nephropathy by nitrated fatty acids*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.

**Nature of the SFI:** Consulting; equity interest; Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.

**Approximate dollar value of the SFI:** Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

46. *FCOI eliminated June 13, 2019*

**Date Disclosed:** September 1, 2016

**Investigator with FCOI:** Stacy Gelhaus Wendell, Ph.D.

**Title:** Research Assistant Professor of Pharmacology & Chemical Biology

**PHS Funding:** NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$10,000 - \$19,999

47.

**Date Disclosed:** September 1, 2016

**Investigator with FCOI:** Bruce Freeman, Ph.D.

**Title:** Professor and Chair of Pharmacology and Chemical Biology

**PHS Funding:** NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

48. *FCOI eliminated April 27, 2018*

**Date Disclosed:** September 1, 2016

**Investigator with FCOI:** Steven Woodcock, Ph.D.

**Title:** Research Instructor, Department of Pharmacology & Chemical Biology

**PHS Funding:** NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$10,000 - \$19,999

49. *FCOI eliminated April 12, 2019*

**Date Disclosed:** September 19, 2016

**Investigator with FCOI:** Mark Gladwin, M.D.

**Title:** Professor and Chair of Medicine  
**PHS Funding:** NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** National Institutes of Health  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the National Institutes of Health and licensed to MAST Therapeutics  
**Approximate dollar value of the SFI:** \$5,000 - \$9,999

50. *FCOI eliminated May 25, 2021*

**Date Disclosed:** September 19, 2016  
**Investigator with FCOI:** Bruce Freeman, Ph.D.  
**Title:** Professor and Chair of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*  
**Role on Research Project:** Principal Investigator of bench research and Co-Investigator of human subject research  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

51. *FCOI eliminated June 13, 2019*

**Date Disclosed:** September 19, 2016  
**Investigator with FCOI:** Stacy Gelhaus Wendell, Ph.D.  
**Title:** Research Assistant Professor of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** \$10,000 - \$19,999

52. *FCOI eliminated April 27, 2018*

**Date Disclosed:** September 19, 2016  
**Investigator with FCOI:** Steven Woodcock, Ph.D.  
**Title:** Research Instructor, Department of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** \$10,000 - \$19,999



53. *FCOI eliminated March 20, 2018*

**Date Disclosed:** September 23, 2016

**Investigator with FCOI:** Matthew Neal, M.D.

**Title:** Assistant Professor of Surgery and Critical Care Medicine

**PHS Funding:** NIH 1 R35 GM119526-01 *Mechanistic Elucidation and Targeted Therapy of Platelet Dysfunction After Trauma*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

54. *FCOI eliminated March 29, 2017*

**Date Disclosed:** September 23, 2016

**Investigator with FCOI:** Brian Suffoletto, M.D.

**Title:** Assistant Professor of Emergency Medicine

**PHS Funding:** NIH 1 R01 AA23650-01A1 *Mechanisms of Change for an Effective Alcohol Text Message Intervention*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to healthStratica

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

55.

**Date Disclosed:** September 27, 2016

**Investigator with FCOI:** Patricia Opresko, Ph.D.

**Title:** Associate Professor of Environmental and Occupational Health

**PHS Funding:** NIH 2 R44 GM108187-03 *GammaPNA Miniprobos for Telomere Analysis and RNA FISH*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to PNA Innovations, Inc.

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

56. *FCOI eliminated June 13, 2019*

**Date Disclosed:** October 5, 2016

**Investigator with FCOI:** Stacy Gelhaus Wendell, Ph.D.

**Title:** Research Assistant Professor of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 1 U54 DK112079-01 *University of Pittsburgh O'Brien Cooperative Research Center Program*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** \$10,000 - \$19,999

57.

**Date Disclosed:** October 10, 2016  
**Investigator with FCOI:** Guergana Savova, Ph.D.  
**Title:** Associate Professor of Pediatrics, Harvard Medical School and Computational Health Informatics Program at Boston Children's Hospital  
**PHS Funding:** NIH 5 U24 CA184407-03 *Cancer Deep Phenotype Extraction from Electronic Medical Records*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Wired Informatics, LLC  
**Nature of the SFI:** Equity interest  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

58. *FCOI eliminated June 17, 2021*

**Date Disclosed:** October 18, 2016  
**Investigator with FCOI:** John Kellum, M.D.  
**Title:** Professor and Vice Chair for Research, Department of Critical Care Medicine  
**PHS Funding:** NIH 1 R01 DK106256-01A1 *Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** bioMérieux and Astute Medical (a subsidiary of bioMérieux)  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** \$20,000 - \$39,999

59. *FCOI eliminated July 19, 2017*

**Date Disclosed:** October 25, 2016  
**Investigator with FCOI:** Alexander Deiters, Ph.D.  
**Title:** Professor of Chemistry  
**PHS Funding:** NIH 1 R21 HD 85206-01A1 *Optical Control of Translation and Gene Editing in Zebrafish Embryos*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** North Carolina State University

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to North Carolina State University

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

60.

**Date Disclosed:** October 26, 2016

**Investigator with FCOI:** Bonnie Hall, Ph.D.

**Title:** Research Instructor, Department of Microbiology & Molecular Genetics

**PHS Funding:** NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Oncorus

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$10,000 - \$19,999

61. *FCOI eliminated April 30, 2018*

**Date Disclosed:** November 2, 2016

**Investigator with FCOI:** Mary Loghmani, P.T., Ph.D.

**Title:** Associate Professor of Physical Therapy, Indiana University

**PHS Funding:** NIH 5 P2C HD086843-02 *Alliance for Regenerative Rehabilitation Research & Training (AR3T)*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Health Smart Technologies, Inc.

**Nature of the SFI:** Equity interest

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

62. *FCOI eliminated March 3, 2018*

**Date Disclosed:** November 17, 2016

**Investigator with FCOI:** Maliha Zahid, M.D., Ph.D.

**Title:** Research Instructor, Department of Developmental Biology

**PHS Funding:** NIH 1 UL1 TR 001857-01 *University of Pittsburgh Clinical and Translational Science Institute*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

63.

**Date Disclosed:** January 4, 2017

**Investigator with FCOI:** Lee M. Ritterband, Ph.D.

**Title:** Professor of Psychiatry and Neurobehavioral Sciences, University of Virginia

**PHS Funding:** NIH 1 R03 HL135213-01 *Feasibility and Acceptability of an internet-based cognitive-behavioral treatment for insomnia in adults with asthma*

**Role on Research Project:** Consultant

**Name of Entity in which Significant Financial Interest (SFI) is held:** BeHealth Solutions, LLC

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Virginia and licensed to BeHealth Solutions, LLC; equity interest

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

64.

**Date Disclosed:** January 17, 2017

**Investigator with FCOI:** Yadong Wang, Ph.D.

**Title:** Professor, Department of Bioengineering

**PHS Funding:** NIH 7 R21 EB016774-03 *Biomimetic Coacervate Delivery of Muscle Stem Cell to Improve Cardiac Repair*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

65.

**Date Disclosed:** March 2, 2017

**Investigator with FCOI:** Kenneth W. Kinzler, PhD

**Title:** Professor of Oncology, Johns Hopkins University

**PHS Funding:** NIH 2 U01 CA152753-06 *ctDNA for the Early Detection and Monitoring of Colorectal Cancer*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Sysmex Corporation

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to Johns Hopkins University and licensed to Sysmex Corporation; payment for services

**Approximate dollar value of the SFI:** Intellectual property royalty distributions between \$60,000 - \$79,999; payment for services between \$60,000-\$79,999

66.

**Date Disclosed:** June 21, 2017

**Investigator with FCOI:** Joseph Glorioso, PhD

**Title:** Professor of Microbiology & Molecular Genetics

**PHS Funding:** NIH 5 R01 CA175052-04 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Oncorus

**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

**Approximate dollar value of the SFI:** Consulting income between \$100,000 - \$149,999; equity interest between \$450,000 - \$499,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

67.

**Date Disclosed:** July 26, 2017

**Investigator with FCOI:** Beibei Bill Chen, PhD

**Title:** Associate Professor of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine

**PHS Funding:** NIH 5 UH3 HL123502 *A New Genus of Ubiquitin-Based Anti-Inflammatories for COPD*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Koutif Therapeutics

**Nature of the SFI:** equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Koutif Therapeutics

**Approximate dollar value of the SFI:** Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interests are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

68.

**Date Disclosed:** July 26, 2017

**Investigator with FCOI:** Rama K. Mallampalli, MD

**Title:** Division Chief, Division of Pulmonary, Allergy, and Critical Care Medicine

**PHS Funding:** NIH 5 UH3 HL123502 *A New Genus of Ubiquitin-Based Anti-Inflammatories for COPD*

**Role on Research Project:** Principal Investigator of bench, and Co-Investigator of animal, research

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Koutif Therapeutics

**Nature of the SFI:** equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Koutif Therapeutics

**Approximate dollar value of the SFI:** Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

69.

**Date Disclosed:** July 26, 2017

**Investigator with FCOI:** Xiang-Qun (Sean) Xie, PhD, EMBA

**Title:** Associate Dean for Research Innovation and Professor, Department of Pharmaceutical Sciences

**PHS Funding:** NIH 1 R44 CA210882 *SQSTM1/P62-Targeted Small Molecules for Multiple Myeloma Disease*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** ID4Pharma, LLC

**Nature of the SFI:** equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned/licensed to ID4Pharma

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

70.

**Date Disclosed:** August 9, 2017

**Investigator with FCOI:** John M. Kirkwood, MD

**Title:** Professor of Medicine, Division of Hematology/Oncology

**PHS Funding:** NIH 5 U01 CA180820 *ECOG-ACRIN Operations Center*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Novartis

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$10,000 - \$19,999

71.

**Date Disclosed:** October 12, 2017

**Investigator with FCOI:** Steven Moulton, MD

**Title:** Professor of Surgery, University of Colorado School of Medicine

**PHS Funding:** NIH 7 UM1 HL120877 *Analysis and Characterization of Trauma-Induced Coagulopathy*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Flashback Technologies, Inc.

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Colorado and licensed to Flashback Technologies, Inc.; equity interest; consulting; management position

**Approximate dollar value of the SFI:** Consulting income between \$10,000-\$19,999; intellectual property rights between \$10,000-\$19,999; management position is unpaid; equity interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

72.

**Date Disclosed:** November 8, 2017

**Investigator with FCOI:** Francisco Schopfer, Ph.D.

**Title:** Research Associate Professor of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 5 R01 HL132550 *Anti-Inflammatory Lipid Mediators in Asthma*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.  
**Approximate dollar value of the SFI:** Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

73.

**Date Disclosed:** November 15, 2017  
**Investigator with FCOI:** Ling Wang, MD, PhD  
**Title:** Research Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine  
**PHS Funding:** NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*  
**Role on Research Project:** Co-Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.  
**Nature of the SFI:** Equity interest  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

74.

**Date Disclosed:** November 15, 2017  
**Investigator with FCOI:** Charles F. McTiernan, PhD  
**Title:** Research Associate Professor of Medicine, Division of Cardiology  
**PHS Funding:** NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*  
**Role on Research Project:** Co-Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.  
**Nature of the SFI:** Equity interest  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

75.

**Date Disclosed:** November 16, 2017  
**Investigator with FCOI:** Jesus Tejero Bravo, PhD  
**Title:** Associate Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine  
**PHS Funding:** NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.

**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

**Approximate dollar value of the SFI:** Management position income between \$5,000 - \$9,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

76.

**Date Disclosed:** November 16, 2017

**Investigator with FCOI:** Jason J. Rose, MD, MBA

**Title:** Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

**PHS Funding:** NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.

**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

**Approximate dollar value of the SFI:** Management positions income between \$10,000-\$19,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

77.

**Date Disclosed:** November 16, 2017

**Investigator with FCOI:** Mark T. Gladwin, MD

**Title:** Chair, Department of Medicine

**PHS Funding:** NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.

**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

**Approximate dollar value of the SFI:** Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

78.

**Date Disclosed:** November 20, 2017

**Investigator with FCOI:** Jesus Tejero Bravo, PhD

**Title:** Associate Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

**PHS Funding:** NIH 5 R21 ES027390 *Countermeasure Therapeutics for Acute Lung Injury*



**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.

**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

**Approximate dollar value of the SFI:** Management position income between \$5,000 - \$9,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

79.

**Date Disclosed:** January 26, 2018

**Investigator with FCOI:** John Kellum, MD

**Title:** Professor and Vice Chair for Research, Department of Critical Care Medicine

**PHS Funding:** NIH 1 R21 DK113486 *Biochemical and Reno-Protective Effects of Remote Ischemic Preconditioning on Contrast-Induced Kidney Disease*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** bioMérieux and Astute Medical (a subsidiary of bioMerieux)

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$20,000 - \$39,999

80.

**Date Disclosed:** March 5, 2018

**Investigator with FCOI:** Stephen F. Badylak, DVM, PhD, MD

**Title:** Professor, Department of Surgery and Deputy Director of the McGowan Institute for Regenerative Medicine (MIRM)

**PHS Funding:** NIH 5 F31 CA210694 *Understanding Esophageal Adenocarcinoma Progression Using Inflammatory and Neoplastic Extracellular Matrix Hydrogels*

**Role on Research Project:** Primary Mentor

**Name of the Entity in which Significant Financial Interest (SFI) is held:** ECM Therapeutics, Inc. (formerly Restoure, Inc.)

**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to ECM Therapeutics, Inc. (formerly Restoure, Inc.).

**Approximate dollar value of the SFI:** Management position income between \$100,000 - \$149,999; equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

81. *FCOI eliminated April 1, 2020*

**Date Disclosed:** June 19, 2018

**Investigator with FCOI:** Dario A. Vignali, PhD

**Title:** Professor and Vice Chair, Department of Immunology

**PHS Funding:** NIH 1 R01 CA228181-01A1 *Targeting TIGIT and PD-1 in Melanoma*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Potenza Therapeutics, Inc.

**Nature of the SFI:** Equity interest

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**82.**

**Date Disclosed:** June 19, 2018

**Investigator with FCOI:** Dario A. Vignali, PhD

**Title:** Professor and Vice Chair, Department of Immunology

**PHS Funding:** NIH 1 R01 CA228181-01A1 *Targeting TIGIT and PD-1 in Melanoma*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Bristol-Myers Squibb, Inc.

**Nature of the SFI:** Equity interest; consulting

**Approximate dollar value of the SFI:** Aggregate of equity interest and consulting income between \$40,000 - \$59,999

**83.**

**Date Disclosed:** July 2, 2018

**Investigator with FCOI:** Jason J. Rose, MD, MBA

**Title:** Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

**PHS Funding:** NIH 1 K08 HL136857-01A1 *Discovering and Developing Recombinant Molecular Scavenging Agents for the Treatment of Carbon Monoxide Induced Cardiovascular Dysfunction*

**Role on Research Project:** Principal Investigator of bench, and Co-Investigator of animal research

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.

**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

**Approximate dollar value of the SFI:** Management positions income between \$10,000-\$19,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**84.**

**Date Disclosed:** August 13, 2018

**Investigator with FCOI:** Chakra Chennubhotla, PhD

**Title:** Associate Professor, Department of Computational and Systems Biology

**PHS Funding:** NIH 5 U01 CA204826-03 *Informatics Tools for Tumor Heterogeneity in Multiplexed Fluorescence Images*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** SpIntellx, Inc.

**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SpIntellx, Inc.

**Approximate dollar value of the SFI:** Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**85.**

**Date Disclosed:** August 13, 2018

**Investigator with FCOI:** D. Lansing Taylor, PhD

**Title** Distinguished Professor, Department of Computational and Systems Biology and Director, University of Pittsburgh Drug Discovery Institute

**PHS Funding:** NIH 5 U01 CA204826-03 *Informatics Tools for Tumor Heterogeneity in Multiplexed Fluorescence Images*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** SpIntellx, Inc.

**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SpIntellx, Inc.

**Approximate dollar value of the SFI:** Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**86.**

**Date Disclosed:** August 13, 2018

**Investigator with FCOI:** Jeffrey L. Fine, MD

**Title** Assistant Professor, Department of Pathology

**PHS Funding:** NIH 5 U01 CA204826-03 *Informatics Tools for Tumor Heterogeneity in Multiplexed Fluorescence Images*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** SpIntellx, Inc.

**Nature of the SFI:** Equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SpIntellx, Inc.

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**87.**

**Date Disclosed:** October 24, 2018

**Investigator with FCOI:** Edith Tzeng, MD

**Title** Professor, Department of Surgery

**PHS Funding:** NIH 1 R56 HL142743-01 *Engineering Biologic Topography into Vascular Grafts*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Aruga Technologies, LLC

**Nature of the SFI:** Equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Aruga Technologies, LLC

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

88.

**Date Disclosed:** October 24, 2018

**Investigator with FCOI:** Sachin Velankar, PhD

**Title:** Associate Professor, Department of Chemical and Petroleum Engineering

**PHS Funding:** NIH 1 R56 HL142473-01 *Engineering Biologic Topography into Vascular Grafts*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Aruga Technologies, LLC

**Nature of the SFI:** Equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Aruga Technologies, LLC

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

89. *FCOI eliminated January 30, 2019*

**Date Disclosed:** November 29, 2018

**Investigator with FCOI:** Steven R. Little, PhD

**Title:** Professor and Chair, Department of Chemical and Petroleum Engineering

**PHS Funding:** NIH 5 U24 DE026915-02 *Michigan-Pittsburgh-Wyss Resource Center: Supporting Regenerative Medicine in Dental, Oral and Craniofacial Technologies*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Lavigen, Inc.

**Nature of the SFI:** Equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Lavigen, Inc.

**Approximate dollar value of the SFI:** Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

90.

**Date Disclosed:** February 25, 2019

**Investigator with FCOI:** Dario A.A. Vignali, PhD

**Title:** Professor and Vice Chair, Department of Immunology

**PHS Funding:** NIH 1 R01 AI144422-01 *Structure, Function, and Mechanistic Analysis of LAG3*

**Role on Research Project:** Principal Investigator of bench and animal research, Co-Investigator of animal research

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Bristol-Myers Squibb

**Nature of the SFI:** Equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to Johns Hopkins University/St. Jude Children's Research Hospital, Inc. and licensed to Bristol-Myers Squibb

**Approximate dollar value of the SFI:** Aggregate of equity interest and consulting income between \$40,000 - \$59,999; intellectual property rights between \$20,000 - \$39,999

91.

**Date Disclosed:** February 25, 2019

**Investigator with FCOI:** Dario A.A. Vignali, PhD

**Title:** Professor and Vice Chair, Department of Immunology

**PHS Funding:** NIH 1 R01 AI144422-01 *Structure, Function, and Mechanistic Analysis of LAG3*

**Role on Research Project:** Principal Investigator of bench and animal research, Co-Investigator of animal research

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Merck & Co., Inc.

**Nature of the SFI:** Equity interest

**Approximate dollar value of the SFI:** \$40,000 - \$59,999

92.

**Date Disclosed:** February 28, 2019

**Investigator with FCOI:** Creg J. Workman, PhD

**Title:** Research Assistant Professor, Department of Immunology

**PHS Funding:** NIH 1 R01 AI144422-01 *Structure, Function, and Mechanistic Analysis of LAG3*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Johns Hopkins University/St. Jude Children's Research Hospital, Inc.

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to Johns Hopkins University/St. Jude Children's Research Hospital, Inc. and licensed to Bristol-Myers Squibb

**Approximate dollar value of the SFI:** \$20,000 - \$39,999

93.

**Date Disclosed:** March 11, 2019

**Investigator with FCOI:** William Federspiel, PhD

**Title:** Professor, Department of Bioengineering

**PHS Funding:** NIH 5 R01 HL135482-03 *Ambulatory Assist Lung for Children*

**Role on Research Project:** Principal Investigator of bench research and Co-Investigator of animal research

**Name of the Entity in which Significant Financial Interest (SFI) is held:** ALung Technologies, Inc.

**Nature of the SFI:** Consulting incoming; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to ALung Technologies, Inc.

**Approximate dollar value of the SFI:** Consulting income between \$10,000-\$19,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

94.

**Date Disclosed:** April 23, 2019

**Investigator with FCOI:** Walter Schneider, PhD

**Title:** Professor, Department of Psychology

**PHS Funding:** NIH 1 U01 EB026996-01 *Connectome 2.0: Developing the Next Generation Human MRI Scanner for Bridging Studies of the Micro-, Meso- and Macro-Connectome*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Psychology Software Tools, Inc.

**Nature of the SFI:** Equity interest

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

95.

**Date Disclosed:** May 8, 2019

**Investigator with FCOI:** Walter Schneider, PhD

**Title:** Professor, Department of Psychology

**PHS Funding:** NIH 2 R44 NS103729-02 *Advancing and Calibrating Anisotropic Diffusion MR Imaging Brain Connectome with Taxon Brain Network Diffusion Phantoms*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Psychology Software Tools, Inc.

**Nature of the SFI:** Equity interest

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

96.

**Date Disclosed:** May 17, 2019

**Investigator with FCOI:** John Grefenstette, PhD

**Title:** Professor, Department of Health Policy and Management

**PHS Funding:** NIH 5 P60AA006282-37 (Sub-project ID: 5610) *Framework for Behavioral Risk Models of Alcohol Problems*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Epistemix, Inc.

**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.

**Approximate dollar value of the SFI:** Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

97.

**Date Disclosed:** May 17, 2019

**Investigator with FCOI:** Donald Burke, MD

**Title:** Dean Emeritus, Graduate School of Public Health and Professor, Department of Epidemiology

**PHS Funding:** NIH 5 U54GM088491-10 *Computational Models of Infectious Disease Threats*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Epistemix, Inc.

**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.

**Approximate dollar value of the SFI:** Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

98.

**Date Disclosed:** May 17, 2019

**Investigator with FCOI:** John Grefenstette, PhD

**Title:** Professor, Department of Health Policy and Management

**PHS Funding:** NIH 5 U54GM088491-10 (Sub-project ID: 5080) *Models & Forecasts*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Epistemix, Inc.

**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.

**Approximate dollar value of the SFI:** Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

99.

**Date Disclosed:** May 23, 2019

**Investigator with FCOI:** Donald Burke, MD

**Title:** Dean Emeritus, Graduate School of Public Health and Professor, Department of Epidemiology

**PHS Funding:** CDC 75D30118C01377 *Advancing Analytics to Improve Actionable Changes in the Opioid Overdose Epidemic*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Epistemix, Inc.

**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.

**Approximate dollar value of the SFI:** Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

100.

**Date Disclosed:** May 23, 2019

**Investigator with FCOI:** John Grefenstette, PhD

**Title:** Professor, Department of Health Policy and Management

**PHS Funding:** CDC 75D30118C01377 *Advancing Analytics to Improve Actionable Changes in the Opioid Overdose Epidemic*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Epistemix, Inc.

**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.

**Approximate dollar value of the SFI:** Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**101.**

**Date Disclosed:** June 11, 2019

**Investigator with FCOI:** Shelby O'Connor, PhD

**Title:** Associate Professor of Pathology and Laboratory Medicine at the University of Wisconsin – Madison

**PHS Funding:** NIH 1R01AI142662 *Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Battelle Memorial Institute

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$5,000 - \$9,999

**102.** *FCOI eliminated April 27, 2021*

**Date Disclosed:** June 25, 2019

**Investigator with FCOI:** Joseph Glorioso, PhD

**Title:** Professor, Department of Microbiology & Molecular Genetics

**PHS Funding:** NIH 5 R01 CA222804-02 *Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Oncorus, Inc.

**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

**Approximate dollar value of the SFI:** Consulting income between \$100,000 - \$149,999; equity interest between \$450,000 - \$499,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**103.** *FCOI eliminated April 27, 2021*

**Date Disclosed:** June 25, 2019

**Investigator with FCOI:** William Goins, PhD

**Title:** Research Assistant Professor, Department of Microbiology & Molecular Genetics

**PHS Funding:** NIH 5 R01 CA222804-02 *Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice*



**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Oncorus, Inc.

**Nature of the SFI:** Consulting; equity interest

**Approximate dollar value of the SFI:** Consulting income between \$5,000-\$9,999; equity interest between \$5,000 - \$9,999.

**104.**

**Date Disclosed:** June 24, 2019

**Investigator with FCOI:** Carlos Malvestutto, M.D., M.P.H.

**Title:** Assistant Professor, Ohio State University

**PHS Funding:** NIH 5 UM 1AI068619 *LOC: HIV Prevention Trials Network*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** ViiV Healthcare

**Nature of SFI:** Consulting

**Approximate dollar value:** \$10,000 - \$19,999

**105.**

**Date Disclosed:** July 10, 2019

**Investigator with FCOI:** Jennifer Grandis, M.D.

**Title:** Professor and Associate Vice Chancellor for Clinical and Translational Research, University of California, San Francisco

**PHS Funding:** NIH 5 P50 CA097190-15 *Head and Neck Cancer Spore*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** STAT3 Therapeutics

**Nature of SFI:** Equity interest

**Approximate dollar value:** \$5,000 - \$9,999

**106.**

**Date Disclosed:** August 8, 2019

**Investigator with FCOI:** Mark T. Gladwin, MD

**Title:** Chair, Department of Medicine

**PHS Funding:** NIH 5 P01 HL103455-09 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.

**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the NIH and licensed to Globin Solutions, Inc.

**Approximate dollar value of the SFI:** Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

107.

**Date Disclosed:** August 8, 2019

**Investigator with FCOI:** Charles F. McTiernan, PhD

**Title:** Research Associate Professor of Medicine, Division of Cardiology

**PHS Funding:** NIH 5 P01 HL103455-09 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.

**Nature of the SFI:** Equity interest

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

108.

**Date Disclosed:** October 10, 2019

**Investigator with FCOI:** Bruce Freeman, PhD

**Title:** Professor and Chair, Department of Pharmacology and Chemical Biology

**PHS Funding:** NIH 1 R56 CA233817-01A1 *Inhibition of DNA double strand break repair in TNBC by nitro-fatty acids*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Creegh Pharmaceuticals, Inc.

**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Creegh Pharmaceuticals, Inc.

**Approximate dollar value of the SFI:** Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value. Management positions are unpaid.

109.

**Date Disclosed:** November 21, 2019

**Investigator with FCOI:** Shantanu Chakrabartty, PhD

**Title:** Clifford Murphy Professor of Electrical & Systems Engineering at Washington University in St. Louis

**PHS Funding:** NIH 1R21AR075242-01 *Wireless, Self-Powered Sensors for Continuous and Longer-Term Monitoring of Spinal Fusion Process*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Piezonix, LLC

**Nature of the SFI:** Equity interest

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

110.

**Date Disclosed:** December 3, 2019

**Investigator with FCOI:** Mark T. Gladwin, MD

**Title:** Chair, Department of Medicine

**PHS Funding:** NIH 1 R01 AG058883-01A1 *Nitrite Therapy to Improve Mitochondrial Energetics and Physical Activity in Older Adults*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.

**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the NIH and licensed to Globin Solutions, Inc.

**Approximate dollar value of the SFI:** Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

### 111.

**Date Disclosed:** December 31, 2019

**Investigator with FCOI:** Charles S. Sfeir, DDS, PhD

**Title:** Chair, Department of Periodontics and Preventative Dentistry

**PHS Funding:** NIH 5 U24 DE026915-03 *Michigan-Pittsburgh-Wyss Resource Center: Supporting Regenerative Medicine in Dental, Oral and Craniofacial Technologies*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Emergence Dental, Inc.

**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Emergence Dental, Inc.

**Approximate dollar value of the SFI:** Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value. Management positions are unpaid.

### 112.

**Date Disclosed:** February 6, 2020

**Investigator with FCOI:** Kelly L. Williams, DMD

**Title:** Assistant Professor, Department of Periodontics and Preventative Dentistry

**PHS Funding:** NIH 5 U24 DE026915-03 *Michigan-Pittsburgh-Wyss Resource Center: Supporting Regenerative Medicine in Dental, Oral and Craniofacial Technologies*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Emergence Dental, Inc.

**Nature of the SFI:** Consulting; equity interest

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

### 113.

**Date Disclosed:** February 26, 2020

**Investigator with FCOI:** Tamar Krishnamurti, PhD

**Title:** Assistant Professor, Division of General Internal Medicine, Department of Medicine

**PHS Funding:** NIH 1 R21 MH119450-01A1 *Identification and Prediction of Peripartum Depression from Natural Language Collected in a Mobile Health App*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Naima Health, LLC

**Nature of the SFI:** Equity interest; management positions; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to Carnegie Mellon University and licensed to Naima Health, LLC

**Approximate dollar value of the SFI:** Income from management positions and consulting between \$20,000 - \$39,999; Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**114.**

**Date Disclosed:** February 26, 2020

**Investigator with FCOI:** Hyagriv Simhan, MD, MS

**Title:** Professor, Department of Obstetrics, Gynecology, and Reproductive Sciences

**PHS Funding:** NIH 1 R21 MH119450-01A1 *Identification and Prediction of Peripartum Depression from Natural Language Collected in a Mobile Health App*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Naima Health, LLC

**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Naima Health, LLC

**Approximate dollar value of the SFI:** Management position is unpaid; Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**115.**

**Date Disclosed:** April 14, 2020

**Investigator with FCOI:** Lee M. Ritterband, Ph.D.

**Title:** Professor, Psychiatry and Neurobehavioral Sciences, University of Virginia

**PHS Funding:** NIH 5 R01 HL131587-03 *Improving Asthma Control Using Internet-Based Cognitive-Behavioral Treatment for Insomnia*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** BeHealth Solutions, LLC

**Nature of the SFI:** Equity interest

**Approximate dollar value of the SFI:** \$20,000-39,999

**116.**

**Date Disclosed:** April 29, 2020

**Investigator with FCOI:** Lori Birder, PhD

**Title:** Professor, Division of Renal-Electrolyte, Department of Medicine

**PHS Funding:** NIH 1 R56 AG063753-01 *Role of Purine Dysregulation in the Underactive Bladder*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Deleon Biosciences, Inc.  
**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Deleon Biosciences, Inc.  
**Approximate dollar value of the SFI:** Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

117.

**Date Disclosed:** April 29, 2020  
**Investigator with FCOI:** Edwin K. Jackson, PhD  
**Title:** Professor, Department of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 1 R56 AG063753-01 *Role of Purine Dysregulation in the Underactive Bladder*  
**Role on Research Project:** Principal Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Deleon Biosciences, Inc.  
**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Deleon Biosciences, Inc.  
**Approximate dollar value of the SFI:** Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

118.

**Date Disclosed:** June 8, 2020  
**Investigator with FCOI:** Jesus Tejero Bravo, PhD  
**Title:** Associate Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine  
**PHS Funding:** NIH 1 R42 ES031993-01 *Hemoglobin-Based Antidotes for the Treatment of Carbon Monoxide Poisoning*  
**Role on Research Project:** Principal Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.  
**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.  
**Approximate dollar value of the SFI:** Management position income between \$5,000 - \$9,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

119.

**Date Disclosed:** June 24, 2020  
**Investigator with FCOI:** Mark T. Gladwin, MD  
**Title:** Chair, Department of Medicine

**PHS Funding:** NIH 1 R42 ES031993-01 *Hemoglobin-Based Antidotes for the Treatment of Carbon Monoxide Poisoning*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.

**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

**Approximate dollar value of the SFI:** Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**120.**

**Date Disclosed:** July 28, 2020

**Investigator with FCOI:** Kacey G. Marra, PhD

**Title:** Professor, Department of Plastic Surgery

**PHS Funding:** NIH 1 U24 DE029462-01 *Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center: Advancing Dental, Oral, and Craniofacial Regeneration to Clinical Trial Initiation*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** AxoMax Technologies, Inc.

**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

**Approximate dollar value of the SFI:** Management position is unpaid; Intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**121.**

**Date Disclosed:** August 24, 2020

**Investigator with FCOI:** Samira Kiani, MD

**Title:** Associate Professor, Department of Pathology

**PHS Funding:** NIH 7 R01 EB024562-03 *CRISPR logic circuits for safer and controllable gene therapies*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** SafeGen Therapeutics

**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the Arizona State University and optioned and/or licensed to SafeGen Therapeutics

**Approximate dollar value of the SFI:** Management position is unpaid; Intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**122.**

**Date Disclosed:** August 24, 2020

**Investigator with FCOI:** Mo Reza Ebrahimkhani, MD

**Title:** Associate Professor, Department of Pathology

**PHS Funding:** NIH 7 R01 EB024562-03 *CRISPR logic circuits for safer and controllable gene therapies*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** SafeGen Therapeutics

**Nature of the SFI:** Equity interest (held directly by spouse); management position (held directly by spouse); intellectual property rights (e.g., royalties, patents, copyrights) assigned to the Arizona State University and optioned and/or licensed to SafeGen Therapeutics

**Approximate dollar value of the SFI:** Management position is unpaid; Intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**123.**

**Date Disclosed:** August 30, 2020

**Investigator with FCOI:** Donald Burke, MD

**Title:** Dean Emeritus, Graduate School of Public Health and Professor, Department of Epidemiology

**PHS Funding:** CDC 1 U01 IP001141-01 *Individual-based Simulation of Seasonal and Pandemic Influenza Epidemics*

**Role on Research Project:** Co-investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Epistemix, Inc.

**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.

**Approximate dollar value of the SFI:** Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**124.**

**Date Disclosed:** October 30, 2020

**Investigator with FCOI:** Jason J. Rose, MD, MBA

**Title:** Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine

**PHS Funding:** NIH 5 R01 HL133003-04 *Heme-induced platelet mtROS drives TSP1 release to accelerate PH pathogenesis*

**Role on Research Project:** Co-investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.

**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

**Approximate dollar value of the SFI:** Management positions income between \$10,000-\$19,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**125.**

**Date Disclosed:** November 2, 2020

**Investigator with FCOI:** George K. Gittes, MD

**Title:** Chief, Division of Pediatric Surgery, Department of Surgery

**PHS Funding:** NIH 5 R01 DK112836-04 *Endogenous alpha-to-beta cell transdifferentiation in diabetes*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Genprex, Inc.

**Nature of the SFI:** Consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Genprex, Inc.

**Approximate dollar value of the SFI:** Consulting income between \$20,000-\$39,999; intellectual property rights is an interest whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

126.

**Date Disclosed:** November 2, 2020

**Investigator with FCOI:** George K. Gittes, MD

**Title:** Chief, Division of Pediatric Surgery, Department of Surgery

**PHS Funding:** NIH 2 R01 DK120377-03 *Alpha cell conversion to beta cells in non-human primates*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Genprex, Inc.

**Nature of the SFI:** Consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Genprex, Inc.

**Approximate dollar value of the SFI:** Consulting income between \$20,000-\$39,999; intellectual property rights is an interest whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

127.

**Date Disclosed:** November 20, 2020

**Investigator with FCOI:** Jesus Tejero Bravo, PhD

**Title:** Associate Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine

**PHS Funding:** NIH 5 P01 HL103455-10 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*

**Role on Research Project:** Co-investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.

**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

**Approximate dollar value of the SFI:** Management position income between \$5,000 - \$9,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

128.

**Date Disclosed:** December 2, 2020

**Investigator with FCOI:** Jason Wilson, MD

**Title:** Associate Professor, College of Medicine Internal Medicine, University of South Florida



**PHS Funding:** NIH 1 OT2 HL156812-01 *ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Pfizer, Inc.

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$10,000 - \$19,999

129.

**Date Disclosed:** January 25, 2021

**Investigator with FCOI:** Jingjing Sun, PhD

**Title:** Research Instructor, Department of Pharmaceutical Sciences

**PHS Funding:** NIH 1 R21 CA249649-01A1 *Tumor-permeable nanoparticles for enhanced pancreatic cancer immunochemotherapy*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Duo Oncology, Inc.

**Nature of the SFI:** Equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Duo Oncology, Inc.

**Approximate dollar value of the SFI:** Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

130.

**Date Disclosed:** January 25, 2021

**Investigator with FCOI:** Song Li, MD, PhD

**Title:** Professor, Department of Pharmaceutical Sciences

**PHS Funding:** NIH 1 R21 CA249649-01A1 *Tumor-permeable nanoparticles for enhanced pancreatic cancer immunochemotherapy*

**Role on Research Project:** Co-investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Duo Oncology, Inc.

**Nature of the SFI:** Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Duo Oncology, Inc.

**Approximate dollar value of the SFI:** Equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

131.

**Date Disclosed:** February 17, 2021

**Investigator with FCOI:** Jan Drappatz, MD

**Title:** Associate Professor, Department of Neurology

**PHS Funding:** NIH 5 UM1 CA137443-10 *Adult Brain Tumor Consortium (ABTC)*

**Role on Research Project:** Co-investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Bristol-Myers Squibb  
**Nature of the SFI:** Equity interest  
**Approximate dollar value of the SFI:** \$20,000 - \$39,999

**132.**

**Date Disclosed:** March 12, 2021  
**Investigator with FCOI:** Bruce Freeman, PhD  
**Title:** Professor and Chair, Department of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 1 R21 HL152312-01A1 *Focal delivery of nitro-oleic acid using ultrasound targeted microbubble cavitation for the treatment of microvascular obstruction*  
**Role on Research Project:** Co-investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Creegh Pharmaceuticals, Inc.  
**Nature of the SFI:** Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Creegh Pharmaceuticals, Inc.  
**Approximate dollar value of the SFI:** Equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**133.**

**Date Disclosed:** March 25, 2021  
**Investigator with FCOI:** Robert M.Q. Shanks, PhD  
**Title:** Associate Professor, Department of Ophthalmology  
**PHS Funding:** NIH 3 R01 EY027331-04S1 *NOT-NS-20-030: Use of anchored biologics to treat vesicant induced neovascularization*  
**Role on Research Project:** Principal Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** AnkyrBio LLC  
**Nature of the SFI:** Equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to AnkyrBio LLC  
**Approximate dollar value of the SFI:** Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**134.**

**Date Disclosed:** March 25, 2021  
**Investigator with FCOI:** Jes K. Klarlund, PhD  
**Title:** Adjunct Associate Professor, Department of Ophthalmology  
**PHS Funding:** NIH 3 R01 EY027331-04S1 *NOT-NS-20-030: Use of anchored biologics to treat vesicant induced neovascularization*  
**Role on Research Project:** Co-investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** AnkyrBio LLC

**Nature of the SFI:** Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to AnkyrBio LLC

**Approximate dollar value of the SFI:** Management position income between \$60,000 - \$79,999; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**135.**

**Date Disclosed:** April 1, 2021

**Investigator with FCOI:** Sanjay Mathew, MD

**Title:** Professor, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine

**PHS Funding:** NIH 5 R01 MH113857-04 *Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Alkermes

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$60,000 - \$79,999

**136.**

**Date Disclosed:** April 1, 2021

**Investigator with FCOI:** Sanjay Mathew, MD

**Title:** Professor, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine

**PHS Funding:** NIH 5 R01 MH113857-04 *Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Allergan

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$5,000 - \$9,999

**137.**

**Date Disclosed:** April 1, 2021

**Investigator with FCOI:** Sanjay Mathew, MD

**Title:** Professor, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine

**PHS Funding:** NIH 5 R01 MH113857-04 *Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Intra-Cellular Therapies, Inc.

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$5,000 - \$9,999

138.

**Date Disclosed:** April 1, 2021

**Investigator with FCOI:** Sanjay Mathew, MD

**Title:** Professor, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine

**PHS Funding:** NIH 5 R01 MH113857-04 *Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Janssen Research and Development

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$20,000 - \$39,999

139.

**Date Disclosed:** April 15, 2021

**Investigator with FCOI:** Stephen Y. Chan, MD, PhD

**Title:** Professor, Division of Cardiology, Department of Medicine

**PHS Funding:** NIH 5 R01 HL138437-04 *Molecular Drivers of Vascular Stiffness and Metabolic Dysfunction in HIV-Induced Pulmonary Arterial Hypertension*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Synhale Therapeutics, Inc.

**Nature of the SFI:** Management positions; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and University of Pittsburgh/Brigham Woman's Hospital and optioned to Synhale Therapeutics, Inc.

**Approximate dollar value of the SFI:** Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

140.

**Date Disclosed:** May 20, 2021

**Investigator with FCOI:** Stephen F. Badylak, DMV, PhD, MD

**Title:** Professor, Department of Surgery and Deputy Director of the McGowan Institute for Regenerative Medicine (MIRM)

**PHS Funding:** NIH 1 R21 NS118399-01A1 *Enhancing Neurogenesis for Brain Tissue Regeneration*

**Role on Research Project:** Co-investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** ECM Therapeutics, Inc.

**Nature of the SFI:** Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to ECM Therapeutics, Inc.

**Approximate dollar value of the SFI:** Management position income between \$100,000 - \$149,999; equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**141.**

**Date Disclosed:** May 24, 2021

**Investigator with FCOI:** Robert Desnick, PhD, MD, DSc

**Title:** Professor & Chair Emeritus, Genetics and Genomic Sciences, Mount Sinai School of Medicine

**PHS Funding:** NIH 1 R01 DK124412-01A1 *Beta-catenin inhibition as a novel therapeutic strategy for porphyria*

**Role on Research Project:** Co-investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Alnylam Pharmaceuticals

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$20,000 - \$39,999

**142.**

**Date Disclosed:** July 21, 2021

**Investigator with FCOI:** Lillian Chong

**Title:** Associate Professor, Department of Chemistry

**PHS Funding:** NIH 5 R01 GM115805-07 *High-performance weighted ensemble software for simulation of complex bio-events*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** OpenEye Scientific

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** \$20,000 - \$39,999

**143.**

**Date Disclosed:** August 11, 2021

**Investigator with FCOI:** Mark E. Schurdak, PhD

**Title:** Visiting Research Associate Professor, Department of Computational & Systems Biology

**PHS Funding:** NIH 2 U24 TR002632-03 *Development and Commercialization of the Microphysiological Systems Database as a Sustainable Resource*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** BioSystics, Inc.

**Nature of the SFI:** Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to BioSystics, Inc.

**Approximate dollar value of the SFI:** Equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**144.**

**Date Disclosed:** August 11, 2021

**Investigator with FCOI:** Albert Gough, PhD

**Title:** Research Associate Professor, Department of Computational & Systems Biology

**PHS Funding:** NIH 2 U24 TR002632-03 *Development and Commercialization of the Microphysiological Systems Database as a Sustainable Resource*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** BioSystics, Inc.

**Nature of the SFI:** Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to BioSystics, Inc.

**Approximate dollar value of the SFI:** Equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**145.**

**Date Disclosed:** August 11, 2021

**Investigator with FCOI:** D. Lansing Taylor, PhD

**Title:** Professor, Department of Computational & Systems Biology

**PHS Funding:** NIH 2 U24 TR002632-03 *Development and Commercialization of the Microphysiological Systems Database as a Sustainable Resource*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** BioSystics, Inc.

**Nature of the SFI:** Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to BioSystics, Inc.

**Approximate dollar value of the SFI:** Equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**146.**

**Date Disclosed:** August 24, 2021

**Investigator with FCOI:** Leah Byrne, PhD

**Title:** Assistant Professor, Department of Ophthalmology

**PHS Funding:** NIH 5 UG3 MH120094-03 *A Massive Library of AAVs to Target Transcriptionally-Defined Primate Cell Types*

**Role on Research Project:** Co-investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Newsight Therapeutics

**Nature of the SFI:** Management position; equity interest

**Approximate dollar value of the SFI:** Equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.